These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27757701)

  • 21. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
    Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
    Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population.
    Kong X; Tang L; Ma X; Liu W; Wang Z; Cui M; Xu D
    Int Urol Nephrol; 2015 Sep; 47(9):1547-53. PubMed ID: 26265108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
    Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
    J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD; Makras P; Pikilidou M; Tournis S; Makris K; Bisbinas I; Tsave O; Yovos JG; Yavropoulou MP
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1206-1213. PubMed ID: 29309589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores.
    Liu WT; Kuo HP; Liao TH; Chiang LL; Chen LF; Hsu MF; Chuang HC; Lee KY; Huang CD; Ho SC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1737-44. PubMed ID: 26366066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs.
    Tokumoto H; Tominaga H; Arishima Y; Jokoji G; Akimoto M; Ohtsubo H; Taketomi E; Sunahara N; Nagano S; Ishidou Y; Komiya S; Setoguchi T
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29463015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of bone mineral density in stable kidney transplant recipients.
    Gupta AK; Huang M; Prasad GV
    J Nephrol; 2012; 25(3):373-83. PubMed ID: 21928224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group.
    Fassio A; Andreola S; Gatti D; Pollastri F; Gatti M; Fabbrini P; Gambaro G; Ferraro PM; Caletti C; Rossini M; Viapiana O; Bixio R; Adami G
    Calcif Tissue Int; 2024 Jul; 115(1):23-30. PubMed ID: 38730099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss.
    Nguyen TV; Sambrook PN; Eisman JA
    J Bone Miner Res; 1997 Jan; 12(1):124-35. PubMed ID: 9240735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.
    Ersoy FF; Passadakis SP; Tam P; Memmos ED; Katopodis PK; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis JG; Dombros AN; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis PC; Yavuz M; Tsakiris JD; Dimitriades CA; Yilmaz ME; Gültekin M; Karayalçin B; Yardimsever M; Oreopoulos DG
    J Bone Miner Metab; 2006; 24(1):79-86. PubMed ID: 16369903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Osteoporosis and arterial stiffness: study of 103 women with mild to moderate risk of cardiovascular disease].
    Ageev FT; Barinova IV; Seredenina EM; Orlova IaA; Kuz'mina AE; Masenko VP; Kochetov AG
    Kardiologiia; 2013; 53(6):51-8. PubMed ID: 23953046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.